The First Patient s Intratumoral Administration of Oncolytic Bacteria SalMet-Vec®Was Completed at Shuang Ho Hospital of the Ministry of Health and Welfare in Taiwan.
Guangzhou, China,April 21, 2023-- Guangzhou Sinogen Pharmaceutical Co., Ltd. ("Sinogen Pharmaceutical") announced that its self-developed first-in-class oncolytic bacterial drug, SalMet-Vec®, successfully completed the first trial of intratumoral administration in the Phase I/IIa clinical trial of Shuang Ho Hospital of the Ministry of Health and Welfare in Taiwan for the treatment of advanced solid tumors. This subject is a tumor patient with recurrent lung metastasis after first-line treatment failed. Dr. Cheng Wei-Hong, Chief Physician of Shuang Ho Hospital, serves as the Clinical Trial Director (PI).
At present, the Phase I/IIa clinical trial of SalMet-Vec® intratumoral injection therapy for patients with advanced solid tumors is being carried out in the United States and Taiwan, China. The main purpose is to evaluate the safety and tolerability of genetically modified attenuated Salmonella SalMet-Vec® intratumoral administration in patients with advanced malignant solid tumors, and to evaluate the initial efficacy of SalMet-Vec® in specific tumor subtypes. In addition to Shuang Ho Hospital, clinical trial centers such as the Linkou Chang Gung Memorial Hospital, Taipei Medical University Hospital, Taichung Veterans General Hospital, China Medical University Hospital, and the Gabriel Cancer Center in the United States have successively started recruiting participants.
Previously, Sinogen Pharmaceuticals had started phase I/IIa clinical trials of intravenous administration of SalMet-Vec® in multiple clinical centers in the United States and Taiwan. On the basis of Phase I clinical safety data, Sinogen Pharmaceutical will further carry out key clinical trials of SalMet-Vec® for liver cancer, osteosarcoma, head and neck cancer, lung cancer, melanoma and other indications. Among them, SalMet-Vec® has obtained the Orphan Drug Designation (ODD) granted by the US FDA for its indications for treating liver cancer and osteosarcoma.
About Oncolytic Bacteria Product SalMet-Vec®
Oncolytic Bacteria Product SalMet-Vec® is a first-in-class genetic engineering biological product that can accurately target and rapidly dissolve tumors. SalMet-Vec® carries specific methionine hydrolase through attenuated Salmonella carrier, depriving the necessary amino acids required for tumor growth, thus killing tumor and preventing tumor proliferation. It is an efficient and tumor-targeting product for broad-spectrum solid tumors. Sinogen Pharmaceutical owns complete intellectual property rights and global rights of the oncolytic bacterium SalMet-Vec®, and has applied for over 50 invention patents worldwide, with 22 authorized..
About Sinogen Pharmaceutical
Sinogen Pharmaceutical is a bio-pharmaceutical company committed to the development of innovative biological anti-tumor drugs to meet the global demand for malignant tumor treatment market. The company's visio.
